The therapeutic effect of ofatumumab in pediatric anti-NMDAR encephalitis: A case series
Year: 2024
Type: article
Study design: Case Report
Abstract: Ofatumumab (OFA) is an anti-CD20 antibody. We assessed the therapeutic potential of OFA in five pediatric anti-NMDAR encephalitis patients who showed poor responses to the first-line immunotherapy. OFA treatment showed clinical improvement including alleviation of clinical symptoms and mRS decrease accompanied by anti-NMDAR antibody turning negative in 3 patients and decline in 2 patients. And all patients achieved B cell depletion after OFA treatment. During follow-up, all patients' symptoms were stable. OFA treatment is safe and effective, easy to administer, and favorable for pediatric anti-NMDAE encephalitis patients who are refractory to the first-line immunotherapy.
Source: Heliyon
Authors: Wenlin Wu, Jie Hong, Yanping Ran, Wenxiao Wu, Haixia Zhu, Chi Hou, Yuanyuan Gao, Yulin Tang, Yinting Liao, Wen-Xiong Chen, Xiaojing Li
Language: English
Subfield: Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,100
Award: G8290992389
OpenAlex ID: W4404655128